SCHEMBL2969396

SCHEMBL2969396

CCNC(=O)c1cccc(Oc2ccc(Cl)cc2N)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
PTGDR2 Q9Y5Y4 8/20 0.52
CYP1A2 P05177 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP3A4 P08684 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.50
MAPT P10636 4/20 0.48
LMNA P02545 3/20 0.48
HTT P42858 1/20 0.47
NR1H2 P55055 1/20 0.46
NR1H3 Q13133 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP2D6 P10635 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
PTGDR Q13258 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2964888 0.91 L3MBTL1 (0.53) L3MBTL1PTGDR2CYP1A2CYP2C9CYP2C19
SCHEMBL11097066 0.85 PTGDR2 (0.54) PTGDR2MRGPRX4MAPTLMNANR1H2
SCHEMBL2962039 0.83 USP2 (0.63) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL2961566 0.82 L3MBTL1 (0.60) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL2969271 0.81 CYP1A2 (0.58) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL2960598 0.81 L3MBTL1 (0.61) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL2964389 0.79 L3MBTL1 (0.59) L3MBTL1PTGDR2CYP1A2CYP2C9CYP2C19
SCHEMBL2971919 0.78 MEN1 (0.55) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL4506943 0.78 PTGDR2 (0.66) PTGDR2PTGDR
SCHEMBL2965308 0.77 MAPT (0.55) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 L3MBTL1 2884/4885PTGDR2 4777/4885CYP1A2 877/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 L3MBTL1 2884/4885PTGDR2 4777/4885CYP1A2 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.